ArticleClinical epigenetics2018
Pharmacological inhibition of EZH2 disrupts the female germline epigenome.
Article in Clinical epigenetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- A comprehensive review of histone modifications during mammalian oogenesis and early embryo development.Histochemistry and cell biology · 2025Review
- EZH1/2 plays critical roles in oocyte meiosis prophase I in mice.Biological research · 2024Article
- Inhibition of EED activity enhances cell survival of female germline stem cell and improves the oocytes production during oogenesisOpen biology · 2023Article
- EED is required for mouse primordial germ cell differentiation in the embryonic gonad.Developmental cell · 2022Article
- The methylome of Biomphalaria glabrata and other mollusks: enduring modification of epigenetic landscape and phenotypic traits by a new DNA methylation inhibitor.Epigenetics & chromatin · 2021Article
- EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.Future oncology (London, England) · 2021Article
- Androgen-induced epigenetic modulations in the ovary.The Journal of endocrinology · 2021Review
- X- and Y-Linked Chromatin-Modifying Genes as Regulators of Sex-Specific Cancer Incidence and Prognosis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Review
- NF-κB/NKILA signaling modulates the anti-cancerous effects of EZH2 inhibition.Journal of cellular and molecular medicine · 2019Article
- Identification and Functional Characterization of a New Splicing Variant of EZH2 in the Central Nervous System.International journal of biological sciences · 2019Article
- Loss of maternal EED results in postnatal overgrowth.Clinical epigenetics · 2018Article
- Out of sight, out of mind? Germ cells and the potential impacts of epigenomic drugs.F1000Research · 2018Review
- Gene expression profile of a selection of Polycomb Group genes during zebrafish embryonic and germ line development.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recently discovered drugs that target epigenetic modifying complexes are providing new treatment options for a range of cancers that affect patients of reproductive age. Although these drugs provide new therapies, it is likely that they will also affect epigenetic programming in sperm and oocytes. A promising target is Enhancer of Zeste 2 (EZH2), which establishes the essential epigenetic modification, H3K27me3, during development. Results: In this study, we demonstrate that inhibition of EZH1/2 with the clinically relevant drug, tazemetostat, severely depletes H3K27me3 in growing oocytes of adult female mice. Moreover, EZH2 inhibition depleted H3K27me3 in primary oocytes and in fetal oocytes undergoing epigenetic reprogramming. Surprisingly, once depleted, H3K27me3 failed to recover in growing oocytes or in fetal oocytes. Conclusion: Together, these data demonstrate that drugs targeting EZH2 significantly affect the germline epigenome and, based on genetic models with oocyte-specific loss of EZH2 function, are likely to affect outcomes in offspring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.